Clinical Trial Update: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Adagloxad Simolenin (OBI-822)/OBI-821 as adjuvant therapy for Globo H positive triple-negative breast cancer. The study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Adagloxad Simolenin (OBI-822) (adagloxad simolenin)

Snippet

Sponsor: OBI Pharma, Inc | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING